Eterna Therapeutics P/E Ratio

Eterna Therapeutics (ERNA) currently reports a P/E ratio of -0.24. That is below the Telecommunications sector average of 10.39. Use the charts on this page to explore Eterna Therapeutics's P/E ratio history and peer comparisons.

Eterna Therapeutics's P/E ratio of -0.24 is lower than the Telecommunications sector average of 10.39. That is roughly 102.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Eterna Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -0.24, ERNA can look expensive or cheap only in context — versus its own history, growth rate, and Telecommunications peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -0.24, then check the historical chart for trend and the peer comparison chart for relative positioning. The Telecommunications average is 10.39. From there, open related valuation or income-statement pages for Eterna Therapeutics, and consider following ERNA for alerts when major investors trade the stock.

Eterna Therapeutics is classified in the Telecommunications sector. On P/E ratio, it currently shows -0.24 versus a sector average near 10.39. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Telecommunications are usually more informative than comparing ERNA with unrelated industries.